Jie Dai

Peking University

H指数:32

被引数:3,229

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma

MARCO+肿瘤相关巨噬细胞抑制CD8+ T细胞免疫，以促进肾细胞癌的免疫治疗抵抗

Advanced Science

IF14.1

2025-10-210

OAAI

Correlation of telomere length and DNA damage markers with severity and associated depressive states in patients with OSAS

端粒长度和DNA损伤标志物与OSAS患者严重程度及相关抑郁状态的关联性

Frontiers in Neurology

IF2.8

2025-10-200

OAAI

Identifying GAP43, NMU, and TEX29 as Potential Prognostic Biomarkers for COPD Combined With Lung Cancer Patients Using Machine Learning

使用机器学习识别GAP43、NMU和TEX29作为COPD合并肺癌患者的潜在预后生物标志物

JOURNAL OF GENE MEDICINE

IF2.2

2025-05-200

PRE

Spatiotemporally Controlled Co-Treatment of Lung Cancer and Pulmonary Immune-Related Adverse Events by Inhalable Albumin-Chaperoned Ultrathin MnO2 Nanosheets

可吸入白蛋白分子伴侣的超薄MnO2纳米片对肺癌和肺部免疫相关不良事件的时空控制共同治疗

ACS NANO

IF16

2025-05-160

PRE

Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy

循环血浆外泌体上PD-L2的动态变化作为接受抗PD-1治疗黑色素瘤患者治疗反应的预测指标

JOURNAL OF EXTRACELLULAR VESICLES

IF14.5

2025-03-260

OAAI

The potential high-risk population for lung cancer screening: determination of initial screening age and heterogeneity in histology and sex

TRANSLATIONAL LUNG CANCER RESEARCH

IF3.5

2024-11-010

OAAI

Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes

通过单细胞转录组分析洞察肺腺癌和鳞癌肿瘤微环境的异质性: 对不同免疫治疗结果的影响

JOURNAL OF GENE MEDICINE

IF2.2

2024-06-071

PRE

Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate therapy

FRONTIERS OF MEDICINE

IF3.5

2024-05-140

PRE

Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

IF8

2023-09-042

PRE

The biological functions of maternal-derived extracellular vesicles during pregnancy and lactation and its impact on offspring health

CLINICAL NUTRITION

IF7.4

2023-04-014

PRE

Differentiation-related genes in tumor-associated macrophages as potential prognostic biomarkers in non-small cell lung cancer

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-03-0913

OAAI

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2023-01-024

OAAI

Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2022-12-017

Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III

EUROPEAN JOURNAL OF CANCER

IF7.1

2022-11-012

PRE

Toripalimab (anti-PD-1) versus high-dose interferon-a2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial

ANNALS OF ONCOLOGY

IF65.4

2022-10-0125

OAAI

A phase Ib trial of neoadjuvant oncolytic virus OrienX010 (ori) and anti-PD-1 toripalimab (tori) combo in patients (pts) with resectable stage IIIb-IV (M1a) acral melanoma

ANNALS OF ONCOLOGY

IF65.4

2022-09-013

OAAI

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma

FRONTIERS IN ONCOLOGY

IF3.3

2022-06-303

OAAI

ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2022-05-170

PRE

An Evidence-Based Staging System for Mucosal Melanoma: A Proposal

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2022-04-0923

PRE

EZH2 Inhibitor Enhances the STING Agonist.Induced Antitumor Immunity in Melanoma

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2022-04-0124

OAAI

Jie Dai

个人简介

教育背景

工作经历

荣誉奖项

研究方向